Search

Your search keyword '"J.-M. Pawlotsky"' showing total 109 results

Search Constraints

Start Over You searched for: Author "J.-M. Pawlotsky" Remove constraint Author: "J.-M. Pawlotsky"
109 results on '"J.-M. Pawlotsky"'

Search Results

1. Microdiversity of Enterococcus faecalis isolates in cases of infective endocarditis: selection of non-synonymous mutations and large deletions is associated with phenotypic modifications

2. First cases of Omicron in France are exhibiting mild symptoms, November 2021-January 2022

3. A175 CAN HCV CORE ANTIGEN REPLACE HCV RNA TESTING IN THE ERA OF DIRECT-ACTING ANTIVIRALS?

7. Efficacy and safety of sofosbuvir and daclatasvir for 8 weeks in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus Genotype 3 Infection

8. Longitudinal analysis of HCV full genomes in patients failing NS5A inhibitors reveals the selection of novel amino acid substitutions outside NS5A

9. Sofosbuvir plus ribavirin and sofosbuvir plus daclatasvir-based regimens are suboptimal in genotype 2 patients: real-life experience

10. P0768 : Late mortality in treatment-experienced cirrhotic patients treated with triple therapy including boceprevir or telaprevir in a real-life cohort - ANRS Co 20 cupic

11. Effect of resistance-associated substitutions on retreatment of direct acting antiviral-exposed patients in the real-world setting (ANRS CO22 HEPATHER)

12. Dermohypodermites bactériennes nécrosantes-fasciites nécrosantes, pathologie plurimicrobienne sous diagnostiquée ? Apport de la métagénomique

14. Retreatment of HCV DAA Failures: HCV Infection may be Incurable

15. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C

17. [The liver and Europe]

18. [Virologic techniques for the diagnosis and monitoring of hepatitis B]

21. P0767 : Clinical utility of hepatitis C virus core antigen testing in the monitoring of treatment naïve non-cirrhotic patients receiving an all-oral, interferon-free regimien

23. Hepatitis C virus population dynamics during infection

24. Practical use of hepatitis C and B molecular tools: Belgian guidelines

27. Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study

28. 1094 100% SVR IN IL28B CC PATIENTS TREATED WITH 12 WEEKS OF TELAPREVIR, PEGINTERFERON AND RIBAVIRIN IN THE PROVE2 TRIAL

33. 1190 SILEN-C2: EARLY ANTIVIRAL ACTIVITY AND SAFETY OF BI 201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (PEGIFN/RBV) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO PEGIFN/RBV

37. Molecular tools for the treatment of hepatitis C

38. [The G virus: the orphan virus]

40. Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation

41. [Prevalence of hepatitis C virus infection in pregnant woman on the island of Réunion]

42. 587 A NEW CLASS OF POTENT INHIBITORS OF HCVRNADEPENDANT RNA POLYMERASE

44. Genetic heterogeneity and properties of hepatitis C virus

45. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C

46. Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda

47. 620 Presence of CD4-positive cells in the portal tract on pretreatment liver biopsy is associated with early viral reduction during antiviral treatment of HCV

48. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus

50. 771 SEQUENCE ANALYSIS OF THE HBV PreC/C REGION BY ULTRA-DEEP PYROSEQUENCING AS A PREDICTOR OF ADEFOVIR TREATMENT OUTCOME IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B

Catalog

Books, media, physical & digital resources